TCP Innovations
Biotechnology consultancy providing technical and strategic advisory services across drug development, including CMC, toxicology, DMPK and pharmacology. Services include outsourced/virtual drug development capability, commercial and business development advice, IP strategy and portfolio review, technical due diligence and asset valuation, bespoke technical problem solving, and expert commentary. Part of a group that includes a contract research organisation offering biomarker-related services and a seed investment fund.
Industries
Nr. of Employees
small (1-50)
TCP Innovations
Edmonds, Washington, United States, North America
Services
Provision of domain experts and bespoke advisory projects across CMC, toxicology, DMPK and pharmacology to support programme progression.
Integrated management of outsourced development activities for companies operating a virtual model.
Strategic advice on partnering, licensing and commercialization planning to maximize asset value.
Assessment of patenting strategy and alignment of IP protection with development and commercial plans.
Independent technical reviews to support investment, licensing or M&A decisions.
Access to biomarker assay development and analytical support through an affiliated contract research organisation serving pharmaceutical, diagnostic and academic clients.
Provision of domain experts and bespoke advisory projects across CMC, toxicology, DMPK and pharmacology to support programme progression.
Integrated management of outsourced development activities for companies operating a virtual model.
Strategic advice on partnering, licensing and commercialization planning to maximize asset value.
Assessment of patenting strategy and alignment of IP protection with development and commercial plans.
Independent technical reviews to support investment, licensing or M&A decisions.
Access to biomarker assay development and analytical support through an affiliated contract research organisation serving pharmaceutical, diagnostic and academic clients.
Expertise Areas
- Clinical trial strategy and development
- Biomarker discovery and multiplexed assay support
- Regulatory and IP strategy
- Outsourced/virtual drug development delivery
Key Technologies
- Metabolomics
- Immunomics
- Multiplexed assay platforms
- Biomarker assay development
News & Updates
Overview of dbt tooling and best practices for modular transformations, testing, lineage and analytics engineering.
Discussion on risks of untested hypotheses driving large phase‑3 programmes and the importance of early de‑risking and data-driven decisions in drug development.
Ongoing blog posts covering clinical development strategy, biomarkers, R&D efficiency and investment themes in the life sciences sector.
Overview of dbt tooling and best practices for modular transformations, testing, lineage and analytics engineering.
Discussion on risks of untested hypotheses driving large phase‑3 programmes and the importance of early de‑risking and data-driven decisions in drug development.
Ongoing blog posts covering clinical development strategy, biomarkers, R&D efficiency and investment themes in the life sciences sector.